<DOC>
	<DOCNO>NCT01646398</DOCNO>
	<brief_summary>The purpose study evaluate safety , tolerability immunogenicity single dose 13-valent pneumococcal conjugate vaccine compare single dose 23-valent pneumococcal polysaccharide vaccine Japanese adult age 65 year old old .</brief_summary>
	<brief_title>A Phase 3 Trial Evaluating Safety , Tolerability , Immunogenicity 13-valent Pneumococcal Conjugate Vaccine Japanese Elderly Adults Aged 65 Years Old Older</brief_title>
	<detailed_description />
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>1 . Healthy Japanese male female adult age 65 year old old time enrollment . Subjects preexist stable disease , define disease require significant change therapy hospitalization worsen disease 12 week receipt study vaccine , eligible . 2 . Male female subject childbearing potential must agree use highly effective method contraception throughout study least 28 day last dose study vaccine whichever longer . 1 . History severe adverse reaction include hypersensitivity anaphylaxis associate vaccine vaccine component . 2 . Previous vaccination license experimental pneumococcal vaccine . 3 . Documented Streptococcus pneumoniae infection within past 5 year . 4 . Residence nursing home , longterm care facility , institution requirement semiskilled nursing care .</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>13VPNC</keyword>
	<keyword>23VPS</keyword>
</DOC>